Navigation Links
Marken Validates Top Position in Global Clinical Sample Shipments
Date:3/15/2012

PARIS, March 15, 2012 /PRNewswire/ --  Marken is pleased to share its year-end data which validates that it holds a market-leading position in the shipment of in-bound biological samples to the major central laboratories and to Pharma directly.  In the past 18 months, Marken collected shipments from over 49,000 clinical investigators in 159 countries around the world.  An independent survey* conducted by a major consulting group, confirms that Marken has more than 60% of the specialty courier market in biological samples transportation, and a higher share of the cold chain segment of that same market. Marken also commissioned an in-depth market research study in 2011 with The Avoca Group.  The Avoca Group interviewed over 100 individuals, including current clients, from 74 global pharmaceutical, CRO, laboratory, and sponsor companies who use supply chain services. In the survey, Marken achieved the top score when asked "Who do you consider a leader in clinical trial logistics?"  The qualities attributed to Marken's leading position were cost effectiveness, flexibility, on-time performance and customer service. Marken intends to conduct this survey annually as a means to monitor and improve its client service position.

(Logo: http://photos.prnewswire.com/prnh/20110930/NY78064LOGO )

With its recent expansion in India and continued growth in Asia, Marken continues to broaden its reach and existing outbound shipments for the pharmaceutical industry which will include: drug product shipments, patient kit shipments, active pharmaceutical ingredients (API) shipments and medical devices.  To support the growing demand, Marken has accelerated its development of pharmaceutical service depots in Asia, Europe, North America and Latin America whilst ensuring that the stringent Quality and Performance criteria of the temperature controlled supply chain are met.

"We are pleased to share the 2011 results from our independent research. The growth in biologics and the increasing need for temperature controlled supply chain will encourage more of our clients to use Marken for their time and temperature sensitive shipments," said Wes Wheeler, Marken's CEO.  "We are experts in worldwide collection of patient samples which is derived from the personal visits we make to 49,000 clinical investigators in 159 countries. We have leveraged this expertise to our growing outbound business as well and will continue to expand our reach with new locations and new distribution services in the life science industries."

About Marken
Marken is the leading global clinical supply chain solutions provider dedicated to the pharmaceutical and life sciences industries, supporting over 49,000 clinical investigators in more than 150 countries. Marken integrates Depot and Logistics services into solutions that extend the reach of clinical trials to even the most remote treatment naive geographies.

*Survey Study Funded by Marken


'/>"/>
SOURCE Marken
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Marken Opens New Corporate Offices
2. Marken Strengthens Clinical Trial Distribution Capabilities
3. Marken Appoints New Head of Global Quality Assurance
4. Marken Announces Its New Logistics Operating System: Maestro™
5. Marken Announces Appointment of Christopher OConnell as New Chief Financial Officer
6. Marken Announces the Opening of a Directly Owned Clinical Trial Supply Depot in Singapore
7. Marken Rapidly Responds to Global Supply Chain Security Measures
8. Marken Unveils New Japan Office
9. New Research Validates Results of Previous Studies Demonstrating Tru-D® (Lumalier Corporation) Significantly Reduces Environmental Contamination on Surfaces in Patient Rooms
10. Study Validates Clinical Accuracy of 50% Dose Reduction for Positron Emission Mammography
11. The European Medicines Agency Validates and Accepts Cell Therapeutics Marketing Authorization Application for Pixuvri™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... -- Eli Lilly and Company (NYSE: LLY ... galcanezumab and lasmiditan, two investigational treatments for migraine, at ... taking place Sept. 7-10 in Vancouver ... data from an open-label study evaluating the safety and ... 240 mg) for the prevention of migraine. Galcanezumab is ...
(Date:9/5/2017)... N.J. , Sept. 5, 2017  Getinge, ... has created a vibrant charitable donation program -- ... and support congenital heart defect research by The ... providers and the general public are encouraged to ... and submit the completed artwork to the gallery ...
(Date:9/1/2017)... Michael Penna , President and CEO ... for growth in his response to the July 13, ... seeking a buyer for eMDs. Penna,s company, Complete HealthCare ... Value Added Reseller and national leader in the independent ... "As the healthcare market continues to dictate consolidation, healthcare ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... “The Financial Favor of God; ... Favor of God; Second Edition” is the creation of published author, Brooks Rathell. , ... opportunity to talk to you about the financial favor of God. Not only does ...
(Date:9/20/2017)... ... ... “Monique”: is the story of Monique, whose mother’s deteriorating physical condition forces the ... has owned four beauty salons and written a book regarding the author’s success in ... , “The doctor’s office was only three blocks away, and she could walk it, ...
(Date:9/19/2017)... ... September 19, 2017 , ... Only a few physicians were selected to receive ... Ross A. Clevens, MD, FACS . The founder and medical director of Clevens ... who trained at Yale, Harvard and the University of Michigan. He has served patients ...
(Date:9/19/2017)... ... September 19, 2017 , ... PAPA Healthcare, Inc. announced ... called, “PAPA Healthcare helps fill gaps, provide essential insights, and improve productivity.” ... operations by leveraging PAPA Healthcare’s post-acute productivity and analytics solutions. , St. Vincent’s ...
(Date:9/19/2017)... ... September 19, 2017 , ... Peter Chandonait, ... President’s Malaria Initiative (PMI) Africa Indoor Residual Spraying (AIRS) Project , has ... , The Innovation to Action Award, a USAID Catalyst Award, recognizes USAID staff ...
Breaking Medicine News(10 mins):